Paris-based device company Carthera has announced that its SonoCloud-9 system can help certain drugs pass the brain-blood barrier, as part of positive results from a Phase I/II clinical trial.
The trial examining the SonoCloud-9, designed as an ultrasound-based treatment for a range of brain disorders such as recurrent glioblastoma (rGBM), found that the device demonstrated a safety profile opening the brain blood barrier for the delivery of drug therapies.
